Why the study?
Does cardiac overexpression of OCTN2 improve ejection fraction and reduce interstitial fibrosis in a mouse model of heart failure?
Does cardiac overexpression of OCTN2 improve ejection fraction and reduce interstitial fibrosis in a mouse model of heart failure?
Comprehensive metabolic profiling in a mouse model of heart failure identified decreased carnitine shuttling as an early defect, and therapeutic overexpression of OCTN2 improved cardiac function and reduced fibrosis.
No takes yet. Share an insight, caveat, or question.
Systemic metabolic shifts in TAC mice are hypothesis-generating; human validation needed before translational or therapeutic implications.
Müller et al. (2018) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: